FXYD3 and neoplasm: The targeted FXYD3 nano‐delivery system (siFXYD3@PEP) exhibited significant antitumor efficacy in spontaneous and transplanted tumor models and markedly enhanced the sensitivity of ICC to standard gemcitabine and cisplatin chemotherapy.